Ruxolitinib: Landmark vitiligo cream targets immune cells that disrupt pigmentation
Revolutionary Vitiligo Cream Set to Transform Lives on the NHS In a groundbreaking development for dermatology and autoimmune skin conditions, a revolutionary cream called ruxolitinib—marketed as Opzelura—is poised to become the first NHS-approved treatment that directly targets the underlying cause of vitiligo. This milestone represents not just a medical breakthrough, but a profound shift in […]
